The historical rank and industry rank for Global Blood Therapeutics's PB Ratio or its related term are showing as below:
GBT'
s PB Ratio Range Over the Past 10 Years
Min: 5.16 Med: 7.7 Max: 38.94
Current: 38.94
During the past 9 years, Global Blood Therapeutics's highest PB Ratio was 38.94. The lowest was 5.16. And the median was 7.70.
GBT's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.5
vs GBT: 38.94
During the past 12 months, Global Blood Therapeutics's average Book Value Per Share Growth Rate was -65.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -33.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -7.50% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Global Blood Therapeutics was 29.00% per year. The lowest was -33.40% per year. And the median was 11.20% per year.
Back to Basics: PB Ratio
Global Blood Therapeutics PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Global Blood Therapeutics's PB Ratio
For the Biotechnology subindustry, Global Blood Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Blood Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Global Blood Therapeutics's PB Ratio falls into.
Global Blood Therapeutics PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Global Blood Therapeutics (NAS:GBT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Global Blood Therapeutics PB Ratio Related Terms
Thank you for viewing the detailed overview of Global Blood Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Global Blood Therapeutics (Global Blood Therapeutics) Business Description
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GBT has been successfully added to your 